Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that is has received Notice of Allowance for the patent titled, “Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy,” from the Japanese, Chinese, Eurasian, Brazilian, and Mexican patent authorities. These patent allowances in key global regions follow prior allowances for the same patent in the US, Europe, Australia and Canada.
The patent provides composition of matter and use protection for the Cellectar’s Phospholipid Drug Conjugate™ (PDC) platform as a targeted delivery vehicle in combination with a class of small molecules known as flavaglines. Flavaglines are a family of natural (plant derived) cytotoxic molecules that, when targeted to cancer, have been shown to kill the tumor cells.
“The expansion of our global IP portfolio supports our plan to develop a diverse product portfolio delivering value across a broad range of therapeutic modalities beyond radiotherapies. In the immediate term, we look forward to reporting topline Waldenstrom’s macroglobulinemia pivotal data for our lead radioconjugate therapy, iopofosine I 131, in January 2024,” said James Caruso, president and CEO of Cellectar. “We are also focused on developing and expanding our pipeline of PDCs in additional high need cancers. Our robust global IP portfolio provides the foundation as we drive forward our mission to transform cancer care for people worldwide.”
